Eisai Co., Ltd. has announced its participation in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, presenting significant findings from its oncology portfolio. The meeting is being held in Chicago, Illinois, and online from May 29 to June 2. Among the notable presentations is a real-world evidence analysis comparing first-line lenvatinib, an orally available multiple receptor tyrosine kinase […]















